What Is Immunotherapy?

Immunotherapy drugs called checkpoint inhibitors block proteins (PD-1, PD-L1, CTLA-4) that cancer cells use to evade immune detection. By removing these "brakes" on your immune system, your T cells can recognize and attack kidney cancer more effectively.

Common agents for kidney cancer include:

  • Nivolumab (Opdivo): PD-1 inhibitor that blocks cancer's ability to hide from T cells.
  • Pembrolizumab (Keytruda): PD-1 inhibitor with proven efficacy in RCC.
  • Ipilimumab (Yervoy): CTLA-4 inhibitor (often combined with nivolumab for synergistic effect).
  • Avelumab (Bavencio): PD-L1 inhibitor (combined with axitinib targeted therapy).

When Is Immunotherapy Used?

First-Line Treatment

For metastatic or advanced clear cell RCC:

  • Nivolumab + ipilimumab: For intermediate/poor-risk disease (40-50% response rate).
  • Pembrolizumab + axitinib: For favorable/intermediate risk (55-60% response rate).
  • Cabozantinib + nivolumab: For all risk groups (50-55% response rate).
  • Lenvatinib + pembrolizumab: For advanced disease (70%+ response rate).

Second-Line & Beyond

  • Patients who progress on VEGF inhibitors (sunitinib, pazopanib).
  • Nivolumab monotherapy approved after prior anti-angiogenic therapy.
  • Cabozantinib monotherapy or lenvatinib + everolimus.
  • Clinical trial options for refractory disease.
  • Salvage immunotherapy combinations for those who failed first-line.

How Immunotherapy Is Given

  • IV infusions: Typically every 2-4 weeks in an outpatient infusion center.
  • Duration: Continued until disease progression or intolerable side effects; some patients remain on therapy for years.
  • Monitoring: Regular CT scans every 8-12 weeks; labs before each infusion to check liver, kidney, and thyroid function.
  • Response assessment: May take 2-3 months to see benefit; tumors sometimes appear larger initially before shrinking (pseudoprogression).
  • Combination protocols: When combining with targeted therapy, both drugs given on scheduled cycles.

Expected Outcomes

Response Rates

  • Nivolumab + ipilimumab: 40-50% objective response rate in intermediate/poor-risk patients.
  • Pembrolizumab + axitinib: 55-60% response rate across risk groups.
  • Cabozantinib + nivolumab: 50-55% response rate with excellent progression-free survival.
  • Lenvatinib + pembrolizumab: 70%+ response rate (highest in class).
  • Monotherapy: 20-25% response rate post-prior therapy.

Survival Benefits

  • Median overall survival: 40-50+ months with combination therapy (vs. 25-30 months with older therapies).
  • Durable responses in 10-20% of patients (multi-year disease control or cure).
  • Improved quality of life compared to older cytokine therapies (interferon, IL-2).
  • Complete responses (cancer disappears) in 5-10% of patients.
  • Some patients able to discontinue therapy after sustained complete response.

Potential Side Effects

Immune-related adverse events (irAEs): Occur when the activated immune system attacks healthy tissue. Most are manageable but require prompt recognition and treatment.

Common (20-40%)

  • Skin rash, itching, vitiligo
  • Diarrhea or colitis
  • Fatigue
  • Thyroid dysfunction (hypo- or hyperthyroidism)
  • Nausea, decreased appetite

Less Common but Serious

  • Hepatitis (liver inflammation)
  • Pneumonitis (lung inflammation)
  • Adrenal insufficiency
  • Nephritis (kidney inflammation)
  • Myocarditis (rare but potentially life-threatening)

Management: Most irAEs are manageable with steroids or temporary drug holds. Our team monitors closely with labs before each infusion and intervenes early. Severe reactions occur in 10-20% but are usually reversible with prompt treatment.

Combination Therapy: Immunotherapy + Targeted Therapy

Combining checkpoint inhibitors with VEGF inhibitors (axitinib, cabozantinib, lenvatinib) improves outcomes over either alone:

  • Rationale: VEGF inhibitors starve tumors by blocking blood vessel growth; immunotherapy attacks cancer cells directly. Together they create a "one-two punch" effect.
  • Evidence: KEYNOTE-426, CheckMate 9ER, and CLEAR trials show superior overall survival and response rates with combinations vs. single-agent therapy.
  • Side Effects: Combination therapy has more side effects than either alone (typically manageable with dose adjustments and supportive care).
  • Monitoring: More frequent labs and closer follow-up required to catch side effects early.

Clinical Outcomes Data

40-70% Objective response rates with modern combinations
40-50 months Median overall survival with first-line combos
10-20% Durable multi-year responses or cures
5-10% Complete response rate (cancer disappears)

Landmark Trials: CheckMate 214, KEYNOTE-426, CheckMate 9ER, CLEAR have established immunotherapy combinations as the new standard of care for metastatic RCC.

Treatment Selection: Which Immunotherapy Is Right for You?

Our multidisciplinary team considers multiple factors:

  • Risk stratification: IMDC criteria (International Metastatic RCC Database Consortium) classify patients as favorable, intermediate, or poor-risk.
  • Prior treatments: First-line vs. second-line determines options.
  • Tumor histology: Clear cell RCC responds best; non-clear cell variants may require different approaches.
  • Sites of metastases: Bone, brain, or liver involvement may influence treatment choice.
  • Performance status: How well you tolerate daily activities affects therapy intensity.
  • Comorbidities: Heart disease, autoimmune conditions, or other factors guide drug selection.
  • Clinical trial availability: Novel agents or combinations may be appropriate for select patients.

Why Advanced Urology?

  • Multidisciplinary kidney cancer team — urology, medical oncology, radiation oncology, and interventional radiology coordinate your care.
  • Access to latest FDA-approved immunotherapies and cutting-edge clinical trials testing novel combinations.
  • Comprehensive supportive care — specialized nurses, nutritionists, and support staff manage immune-related side effects.
  • Tumor board reviews for every complex case ensuring optimal, personalized treatment selection.
  • Integrated imaging and pathology — rapid turnaround for scans and biopsies to guide therapy adjustments.
  • Patient navigation — dedicated coordinators help with scheduling, insurance, and treatment logistics.

Frequently Asked Questions

How long will I be on immunotherapy?

Most patients continue until disease progression or intolerable side effects. Some protocols allow stopping after 1-2 years if complete response is achieved. Responses often persist after stopping due to immune memory.

Will I lose my hair?

No. Unlike chemotherapy, immunotherapy does not cause hair loss. Side effects relate to immune activation (rash, colitis, etc.) rather than general cell toxicity.

Can I work during treatment?

Many patients continue working. Infusions are outpatient, typically taking 30-60 minutes. Most side effects are manageable. Fatigue is common but varies by individual and often improves after first few cycles.

What if immunotherapy stops working?

We have multiple lines of therapy including other immunotherapy combinations, different targeted therapies, clinical trials, or localized treatments (surgery, radiation, ablation) for oligometastatic disease.

Are there long-term side effects?

Most side effects resolve after stopping therapy. Some (like thyroid dysfunction) may be permanent but are easily managed with daily medication. Serious long-term effects are rare with proper monitoring.

How is immunotherapy different from chemotherapy?

Immunotherapy trains your immune system to fight cancer; chemotherapy directly kills rapidly dividing cells. Immunotherapy has different (often more tolerable) side effects and can produce durable responses that last years after stopping treatment.

Next Steps

If you have advanced or metastatic kidney cancer, our multidisciplinary team will evaluate your specific situation, discuss all immunotherapy options, and create a personalized treatment plan to maximize survival and maintain quality of life.

Schedule your evaluation Email our kidney cancer team